Home » Biomanufacturing, chemicals & materials » LabGenius Locks Down $3.66m From Top-Tier Investors To Harness Evolution

LabGenius Locks Down $3.66m From Top-Tier Investors To Harness Evolution

London, UK – 24 November 2017

London-based synthetic biology startup LabGenius has secured $3.66 million in an oversubscribed seed round.

The financing was jointly led by Kindred Capital and Acequia Capital with participation from Backed VCBeast VenturesBerggruen Holdings Ltd, and System.One. The round also included former head of corporate strategy at Microsoft, Charlie Songhurst and prominent angel investor, Tom McInerney.

LabGenius, a pioneer in the use of synthetic biology for the development of new materials, will use the funds to establish a purpose-built R&D facility in Central London and mature EVA – its autonomous AI-driven evolution engine.

“EVA is a Silicon Scientist hooked up to a bank of liquid handling robots. By combining intelligence with empirical exploration, EVA is able to iteratively learn through conducting its own scientific experiments.” says LabGenius founder and CEO, Dr. James Field. “Right now, EVA is unpicking Nature’s design rules with unparalleled speed and dexterity. Once equipped with this knowledge, EVA will give us the ability to engineer life with unprecedented control. Critically, this technology will give us the ability to harness new materials and therapies that we do not or even cannot fully understand.”

Leila Zegna, founding partner at Kindred Capital, commented: “We’re delighted to have backed LabGenius. The company is breaking new ground at the interface of synthetic biology and data science and the potential of their technology is vast”.

For further details, please contact:

James Field, CEO & Founder

Tel    +44 (0) 20 3627 7156

Email    hi@labgeni.us

Notes to Editors:

About LabGenius

LabGenius’ mission is to harness evolution with AI to develop radically new materials. The company’s foundational technology was co-developed by Founder and CEO James Field and CSO Harry Rickerby with financial backing from Innovate UK, BBSRC and SynbiCITE. The company has secured R&D contracts both from the UK Ministry of Defence (MoD) and leading multinationals. LabGenius is run by a multidisciplinary team of synthetic biologists, data scientists and engineers.

For more information, please visit www.labgeni.us

About Kindred Capital

Kindred Capital is a London-based early stage VC fund who uniquely share the upside of the fund with the entrepreneurs that they invest in.  The founding team bring a combination of deep operating, founding, and investing experience.

For more information, please visit www.kindredcapital.vc


Press Release

Click here to join our weekly newsletter. We want to hear what you think about this article. Got a tip for our news team? Write to editorial@synbiobeta.com.

Add comment

Job opportunities